Pharmacological management of anticancer agent extravasation: A single institutional guideline
Open Access
- 1 March 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 24 (2), 129-138
- https://doi.org/10.1177/1078155217690924
Abstract
Although the risk of extravasation of a chemotherapy (anticancer) medication is low, the complications associated with these events can have a significant impact on morbidity and health care costs. Institutions that administer anticancer agents should ideally have a current guideline on the proper management of the inadvertent administration of these toxic medications into tissues surrounding blood vessels. It is imperative that the health care team involved in administering drugs used to treat cancer be educated on the risk factors, preventative strategies and treatment of anticancer extravasations, as well as practice safe and proper administration techniques. Anticancer agents are generally divided into classes based on their ability to cause tissue damage. The review of current published guidelines and available literature reveals a lack of consensus on how these medications should be classified. In addition, many recently approved drugs for the treatment of cancer may lack data to support their classification and management of extravasation events. The treatment of the majority of extravasations of anticancer agents involves nonpharmacological measures, potentially in the ambulatory care setting. Antidotes are available for the extravasation of a minority of vesicant agents in order to mitigate tissue damage. Due to the limited data and lack of consensus in published guidelines, a working group was established to put forth an institutional guideline on the management of anticancer extravasations.Keywords
This publication has 23 references indexed in Scilit:
- Management of Extravasation Injuries: A Focused Evaluation of Noncytotoxic MedicationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Management of chemotherapy extravasation: ESMO–EONS Clinical Practice GuidelinesAnnals of Oncology, 2012
- Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatmentAnti-Cancer Drugs, 2012
- Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studiesAnnals of Oncology, 2006
- Vesicant Extravasation Part I: Mechanisms, Pathogenesis, and Nursing Care to Reduce RiskOncology Nursing Forum, 2006
- Extravasations of OxaliplatinJournal of Clinical Oncology, 2003
- Skin ulceration potential of paclitaxel in a mouse skin model in vivoCancer, 1996
- Hyaluronidase as an antidote to extravasation ofVinca alkaloids: Clinical resultsZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approachCancer Chemotherapy and Pharmacology, 1992